Introduction

Indoleamine 2,3-dioxygenase 1 (IDO1, EC 1.13.11.42) is the first and rate-limiting enzyme in the tryptophan-kynurenine pathway and degrades the essential amino acid L-tryptophan (L-Trp). IDO1 is induced by interferon-γ (IFN-γ)-mediated effects of the signal transducer and activator of transcription 1α (STAT1-α), and interferon regulatory factor 1 (IRF-1) [1]. The induction of IDO1 can also be mediated through an IFN-γ-independent mechanism. The induction of IDO1 by lipopolysaccharide (LPS) is regulated by the p38 mitogen-activated protein kinase (MAPK) pathway and nuclear factor-κB (NF-κB) [2] [3].

The metabolism of L-Trp via IDO1 is accompanied by the production of a series of immunoregulatory metabolites, collectively known as “kynurenines,” which can suppress the proliferation and differentiation of effector T cells [4], and markedly enhance the suppressor activity of regulatory T cells [5]. As a result, IDO1 controls and fine-tunes both innate and adaptive immune responses [6] under a variety of conditions, including pregnancy[7], transplantation[8], infection [9], chronic inflammation [10], autoimmunity [11], neoplasia, and depression[12]. Owing to the outstanding immune-modulate properties of IDO1, IDO1 inhibitors have been searched for in many fields, to control various inflammatory diseases. Thus, it is hoped that the inhibitor of IDO1 becomes the new therapeutic target for drugs corresponding to various inflammatory diseases [13] [14].

Previous researches have given direct evidence of the crucial role of natural products from plants, animals, and microorganisms as potential sources of various modern pharmaceuticals. Currently, phytochemical research is being considered an effective approach in the discovery of novel chemical entities, with potential as drug leads. Previous reports have shown that some food compounds such as epigallocatechin gallate (EGCg; CID 65064) and curcumin (CID 969516) inhibit the induction of IDO1[15] [16].

Therefore, we extracted various compounds from traditional Japanese foods and plants. The purpose of this study was to find a novel effective inhibitor of IDO1 from food and plant compounds. We examined the inhibitory effects of fourteen kinds of plant extracts and sixteen kinds of phytochemicals on the induction of IDO1. Among these compounds, we found that galanal (CID 3050416) isolated from the methanol extract of Myoga flower buds was the most effective inhibitor of IDO1.

Materials and Methods

Materials

Docosahexaenoic acid (DHA, (22:6), CID 445580), eicosapentaenoic acid (EPA, (20:5), CID 446284), epigallocatechin gallate (EGCg; CID 65064), curcumin (CID 969516), epicatechin gallate (ECG; CID 65064), L-kynurenine (CID 446284), 3-hydroxykynurenine (3-HK, CID 446284), 3,4-dihydroxykynurenine (3,4-DHK, CID 446284), and 3,4-dihydroxyanthranilic acid (3,4-DAA, CID 446284) were obtained from the National Institute for Nutrition, Health and Nutrition, Takasaki University of Health and Welfare, Takasaki-City, Gunma, Japan.
EGCG, L-Trp, L-kynurenine (L-Kyn) and recombinant human IFN-γ (rhIFN-γ) were purchased from WAKO Chemical (Tokyo, Japan). DHA and EPA were dissolved in 100% ethanol and each 20 mM solution was prepared for storing at -20°C. The purification of phytochemicals used, except EGCG from plant extracts, and the preparation of plant extracts used were conducted using the same methods as described in previous reports [17].

Cell culture

Human acute leukemic cells, THP-1, and Human embryonic kidney, HEK293, were maintained in RPMI-1640 or DMEM medium supplemented with 10% FCS, at 37°C in a humid atmosphere of 5% CO2. Cells (1x10⁵) were treated with phytochemicals (10 µM) or plant extracts (30 µg/ml), and LPS (50 ng/ml) for 24 hrs.

Figure 1. Effects of plant extracts and phytochemicals on IDO1 induction. (A) The expression of IDO1 mRNA in LPS-stimulated THP-1 cells with and without either plant extracts or phytochemicals. THP-1 cells were incubated with LPS (50 ng/ml) and either plant extracts (30 µg/ml each) or phytochemicals (10 µM each). The levels of IDO1 mRNA were measured using RT-PCR. (B) L-Kyn formation from L-Trp in LPS-stimulated THP-1 cells with and without either plant extracts or phytochemicals. L-Kyn formed in the LPS-stimulated cells with each treatment after 24-hr incubation was measured by HPLC. (C) HEK293 cells transfected with human IDO1 were incubated with galanal, curcumin, andrographolide, quercetin, or luteolin (5 µM each). The concentration of L-Kyn formed after 48-hr incubation was measured by HPLC. Data are expressed as the mean ± SD (n = 3). ***p<0.001, **p<0.01.
doi:10.1371/journal.pone.0088789.g001
Measurement of L-Kyn
L-Kyn in each conditioned medium was measured by the method using high-performance liquid chromatography (HPLC) with a spectrophotometric detector (SHIMADZU, Prominence UFLC), as described in our previous reports [18] [19].

Expression and purification of recombinant IDO1
The human IDO1 cDNA was expressed in E. coli, and purified by a Ni²⁺-column by affinity-binding to the N-His-tag of recombinant IDO1, as described in our previous reports [20]. The resultant IDO1 was enzymatically active when assayed using L-Trp as a substrate. Therefore, this purified IDO1 was used for monitoring IDO1 activity. It is stored at −80°C until use.

Enzyme assay for rIDO1
IDO1 activity was determined by the methylene blue/ascorbate assay as previously described [3]. The reaction mixture contained 50 μl of rIDO and 50 μl of substrate solution. The composition of the substrate solution was 100 mM potassium phosphate buffer (pH 6.5), 50 μM methylene blue, 20 μg of catalase, 50 mM ascorbate, and 0.4 mM L-Trp. After incubating the reaction mixture at 37°C for sixty minutes, samples were acidified with 3% perchloric acid and centrifuged at 7000 g for 10 min at 4°C. The concentrations of the enzymatic products were measured using HPLC. The type of IDO1 inhibition by galanal was determined from the plot of enzyme kinetics.

RNA Extraction and semi-quantitative analysis of RT-PCR products
The total RNA was extracted from cell lines with ISOGEN (Nippon GENE, Tokyo, Japan) and the RNA concentration was determined spectrophotometrically at 260 nm. Reverse transcription-PCR was performed by using Revetra Ace Kits (TOYOBO, Japan). Primers used in semi-quantitative analysis were as follows-GAPDH: 5'-accacagtccatgccatcac (sense) and 5'-tccaccaccc-ctgttgctgta (antisense); IDO1: 5'-ctgacttatgagaacatggacgt (sense) and 5'-atacaccagaccgtctgatagctg (antisense); β-actin: 5'-tgcaccacaccttctacaatga-3' (sense) and 5'-cagcctggatagcaacgtacat-3' (antisense). Semi-quantitative analysis of RT-PCR products was performed by using NIH ImageJ 1.34 s software and normalized to GAPDH. When the same experiment was repeated three times, the three experiments showed similar results. Therefore, the results obtained from one of the three experiments were shown.

Determination of mRNA expression levels using quantitative real-time RT-PCR
To analyze the amount of IDO1 mRNA, real-time PCR was performed by the Applied biosystems 7500 real-time qPCR system (Applied Biosystems, Foster City, USA) using the EvaGreen PCR Master Mix (BioRad, Tokyo, Japan). The mRNA level of IDO1 was normalized to that for β-actin. Primers used in real-time PCR were as follows-IDO1: 5'-GCATTCTTCACTTCTTGTCA-3' (sense) and 5'-CATACACCAAGACCTTGATAGCT-3' (antisense); β-actin: 5'-TGACCCAACCTTTCTACATGA-3' (sense) and 5'-CAGCCTGGATAGCAACGTACAT-3' (antisense).

Protein phosphorylation
Protein phosphorylation was examined with using Phospho-Tracer ELISA kit (Cambridge, UK). Each experiment was performed according to the manufacture protocols.

Statistical analysis
Values obtained, except the kinetic study, are expressed as means ± SD. Statistically significant differences (p<0.05) were analyzed by one-way ANOVA, followed by post-hoc test with Tukey-test. The enzymatic assay of IDO1 in the presence or absence of either each plant extract or each phytochemical was performed in duplicate or triplicate; each assay was repeated at least two or three times. Based on the replicate assays of IDO1 activity in the presence or absence of galanal, the average values of the activities obtained in the replicate assays were shown in all Figures. Each value of IDO1 activity in the replicate assays varied within less than 5% of the average value of the activities.

Results
Effects of plant extracts and phytochemicals on induction of IDO1
First, the effects of fourteen kinds of plants extracts and sixteen kinds of phytochemicals on IDO1 induction were examined, that is, the expression of IDO1 at its mRNA level was examined in LPS stimulated THP-1 cells treated with and without fourteen kinds of plants extracts and sixteen kinds of phytochemicals (Figure 1A).

Figure 2. Effect of galanal on IDO1 activity in different cell species. HEK 293 cells transfected with human IDO1 (A) or mouse IDO1 (B) were treated with various concentrations (1-5 μM) of galanal for 48 hrs. Data are mean ± SD (n = 3). **P<0.01.
doi:10.1371/journal.pone.0088789.g002
Among them, five kinds of plant extracts and five phytochemicals were selected because they had an inhibitory effect on the expression of IDO1 at its mRNA level (Figure 1A). The selected five phytochemicals were luteolin, quercetin, andrographolide, curcumin and galanal. The selected five plant extracts were the extracts of angelica, chrysanthemums, burock, zeodoary, and andrographis. Second, the inhibitory effects of the selected five plant extracts and five phytochemicals on the production of L-Kyn from L-Trp in LPS-stimulated THP-1 cells were examined by measuring the concentration of L-Kyn using HPLC. As shown in Figure 1B, the levels of L-Kyn produced via IDO1 in LPS-stimulated THP-1 cells were reduced extensively by some compounds such as quercetin, luteolin, curcumin, andrographolide and galanal. Thus, andrographolide and galanal present in the extract of Myoga were able to inhibit IDO1 induction. Galanal, especially, had a strong inhibitory effect on IDO1 induction.

Because quercetin, luteolin, curcumin, andrographolide and galanal clearly showed an inhibitory effect on IDO1 induction, we further examined these compounds using IDO1-overexpressed HEK293 cells, to see whether they inhibited the enzymatic activity of IDO1 or not (Figure 1C). Among the five compounds, galanal showed a significant inhibition of the enzymatic activity of IDO1 in IDO1-overexpressed in HEK293 cells.

Inhibitory effect of galanal on IDO1 activity in different cell species

The inhibitory effect of galanal on IDO1 activity was examined in human IDO1-overexpressed cells and mouse IDO1-overexpressed cells in order to clarify the specificity of the compound on IDO1 species. When human IDO1-overexpressed cells and mouse IDO1-overexpressed cells were treated with various concentrations of galanal (1–5 \mu{M}), galanal inhibited both enzymatic activities of human IDO1 and mouse IDO1 in a dose-dependent manner (Figure 2).

Kinetic analysis for IDO1 inhibition by galanal

Results of the kinetic studies of IDO1 using two concentrations (0 and 30 \mu{M}) of galanal were plotted on the Michaelis–Menten model; galanal lowered the Vmax 0.88 folds determinations when Trp was varied, but it had pronounced effects on the apparent Michaelis constants in Figure 3A (Km = 1/2 Vmax, Control; 52.6 \mu{M}, galanal; 74.5 \mu{M}).

The mode of IDO1 inhibition by galanal was examined using the Lineweaver-Burk plot (Figure 3B). Galanal inhibited the activity of the purified recombinant human IDO1 with an increase in its concentration and caused an almost complete inhibition of the enzymatic activity at 30 \mu{M}; the IC50 value of galanal was 7.7 \mu{M}, proving that it inhibited IDO1 activity in a competitive manner (Figure 3C).

Effect of galanal on the NF\kappa-B signal transduction pathway

As shown in Figure 4, galanal inhibited IDO1 induction in LPS-stimulated THP-1 cells, contingent on the dose. The inhibitory ability of galanal was confirmed by measuring the levels of both L-Kyn production and IDO1 mRNA expression (Figure 4A and B). Galanal decreased the expression of IDO1 mRNA in a dose-dependent manner, suggesting that galanal could inhibit signal transduction by LPS stimulus. It is known that LPS stimulus up-regulates IDO1 expression through the NF\kappa-B signal transduction pathway [2,3]. To confirm the effect of galanal on the NF\kappa-B signal transduction pathway, IkB-\alpha expression and the phosphorylation of IKK-\alpha, IkB-\alpha, and NF\kappa-B were examined. Galanal did not decrease the IkB-\alpha expression in LPS-stimulated THP-1 cells (Figure 4C). The phosphorylation of IKK-\alpha, IkB-\alpha, and NF\kappa-B were down-regulated by Galanal (Figure 4D). Galanal was thus found to interfere with the transcriptional function of the NF\kappa-B signaling pathway by reducing the degradation of signal transducer IkB-\alpha.
Effect of galanal on the IFN-γ signal transduction pathway

Galanal inhibited both L-Kyn production and IDO1 mRNA induction in IFN-γ-stimulated THP-1 cells (Figure 5A and B). The phosphorylation of stat1 was down-regulated by Galanal (Figure 5C). Furthermore, galanal interfered with the transcriptional function of the IFN-γ dependent pathway.

Inhibition of cellular IDO1 activity by galanal

Cellular IDO1 inhibition by galanal was examined in LPS-stimulated THP-1 cells. As shown in Figure 6, galanal caused a clear inhibition of the cellular IDO1 activity and when the percentage of inhibition of IDO1 activity by galanal in LPS-stimulated THP-1 cells against control cells was plotted, the IC_{50} value was found to be 45 nM.

Discussion

IDO1 is recognized as one of the prominent mediators of immune regulation by metabolic pathways. Therefore, the regulation of the enzymatic activity of IDO1 is useful in the treatments of tumor, inflammatory diseases, and depression. Previous data have suggested that IDO1 inhibition can modulate immune response, delay tumor growth, and enhance dendritic cell vaccines [21] [22]. A frequently used IDO1 inhibitor is 1-methyl-tryptophan (1-MT). Several studies have provided evidence that IDO1 inhibition with 1-MT or other small molecule inhibitors can exert antitumor effects [23] [24]. Initial evidence, in 2002, showed that IDO1 inhibitor 1-MT could partly retard growth of mouse melanoma cells engrafted onto a syngeneic host [25]. A recent report showed that 1-MT with an anticancer drug, improved tumor prognosis [26]. It seems that D-1-methyl-tryptophan (D-1-
MT) selected for phase I trials has immune modulating activity in the United States [24]. However, some reports have shown that D-1-MT inhibits IDO2, a recently identified IDO1 isoform, more selectively than IDO1 [27] [28] [29]. The mechanisms by which D-1-MT inhibits IDO1 and IDO2 have yet to be cleared.

Considerable attention has been paid to the research of effective IDO1 inhibitors [30][31][32]. The IDO1 inhibitor search was based on indole-based structures, combination of docking-based pharmacophore model development, and several natural products. Among the IDO1 inhibitors studied so far, it was seen that phytochemicals such as EGCG and curcumin inhibited the activity of IDO1 [15,16]. To find a new, effective IDO1 inhibitor, we examined the ability of various phytochemicals to inhibit IDO1 activity: galanal was found to have a strong ability to inhibit IDO1 activity in a competitive manner. Galanal is extracted from Myoga, a perennial herb with pungently aromatic flower buds, native to Eastern Asia. In Japan, the flower buds of Myoga are used as a spice and eaten as pickles. The labdane-type diterpene trialdehydes, 12(E)-lab-dene-15,16,(8b),17-trial(miogatrial), galanal A, and galanal B, are found in Myoga flower buds and exhibit certain biological activities[17] [33].

Though many inhibitors for IDO1 have been found, there are few inhibitors with competitive inhibition. In the present study, galanal was found to possess more IDO1 inhibitory potency than either the most-commonly used 1-MT or other previously-published inhibitors (Table. 1) [14] [28] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43]. Since the IC50 value of inhibitor depends on the IDO1 enzyme activity in each experiment, we could not unconditionally compare the previous results. However, these results showed that galanal is an effective IDO1 inhibitor because a very low dosage of it showed inhibitory activity in the cell-based assay.

IDO1 is known to be induced by both the IFN-γ-dependent pathway and the IFN-γ-independent pathway, i.e., the NF-kB-dependent pathway [2] [3]. Galanal inhibited not only the 1 cells with and without galanal (1-5 μM) after 24-hr incubation. IDO1 mRNA expressed in IFN-γ-treated THP-1 cells with and without galanal was measured using RT-PCR. (C) The phosphorylation of stat1 in IFN-γ (100 U)-treated THP-1 cells with and without galanal after 15-min or 30-min incubation. n. Data are the mean ± SD. ***P<0.001. doi:10.1371/journal.pone.0088789.g005

Figure 5. Inhibition by galanal of the IFN-γ dependent pathway. (A) L-Kyn formation in IFN-γ (100U)-treated THP-1 cells with and without various concentrations (1-5 μM) of galanal. L-Kyn formed after 24-hr incubation was measured by HPLC. Data are the mean ± SD. ***P<0.001. (B) Expression of IDO1 mRNA in IFN-γ (100 U)-treated THP-1 cells with and without galanal (1-5 μM) after 24-hr incubation. IDO1 mRNA expressed in IFN-γ (100 U)-treated THP-1 cells with and without galanal was measured using RT-PCR. (C) The phosphorylation of stat1 in IFN-γ (100 U)-treated THP-1 cells with and without galanal after 15-min or 30-min incubation. n. Data are the mean ± SD. ***P<0.001. doi:10.1371/journal.pone.0088789.g005

Figure 6. Inhibition of cellular IDO1 activity by galanal. LPS-stimulated THP-1 cells were exposed to various concentrations of galanal. Percentage inhibition in LPS-stimulated THP-1 cells against control cells was plotted and IC50 value determined. doi:10.1371/journal.pone.0088789.g006
Enzymatic activity of IDO1 but also suppressed the signal transduction associated with the expression of IDO1 mRNA. Namely, a very low dose of galanal inhibited the expression of IDO1 mRNA induced by the NF-κB-dependent pathway clearly. In addition, it was suggested that galanal could inhibit the expression of IDO1 mRNA induced by the IFN-γ-dependent pathway. NF-κB is activated by various stimuli such as free radicals, inflammatory stimuli, cytokines, carcinogens, tumor promoters, endotoxins, radiation, and ultraviolet light [44]. Upon activation, NFκ-B induces the expression of more than 200 genes known to suppress apoptosis and also induces cellular transformation, proliferation, invasion, metastasis, chemoresistance, radio-resistance, and inflammation [45]. Many of the target genes that are activated are critical to the establishment of inflammation and tumor [46]. Therefore, control of the NFκ-B signal transduction may be useful for treatments of tumor and inflammatory diseases.

Our results have shown that galanal is an effective compound in immunomodulation, because the compound inhibits both the certain signal transduction and enzymatic activity of IDO1 at a very low dose.

### References

1. Hassanain HH, Chon SY, Gupta SL (1993) Differential regulation of human indoleamine 2,3-dioxygenase gene-expression by interferon-gamma and interferon-alpha-analysis of the regulatory region of the gene and identification of an interferon-gamma-inducible DNA-binding factor. Journal of Biological Chemistry 268: 5077–5084.

2. Fujigaki H, Saito K, Fujigaki S, Takemura M, Sudo K, et al. (2006) The signal transducer and activator of transcription 1 alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: Involvement of p38 mitogen-activated protein kinase and nuclear Factor-kappa B pathways, and synergistic effect of several proinflammatory cytokines. Journal of Biochemistry 139: 655–662.

3. Fujigaki S, Saito K, Sekikawa K, Tone S, Takakawa O, et al. (2001) Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. European Journal of Immunology 31: 2313–2318.

### Conclusion

The results of the present study indicate that galanal is a competitive IDO1 inhibitor. The results also indicate that a very low dose of galanal inhibits not only the enzymatic activity of IDO1 but also the expression of IDO1 mRNA induced by the NF-κB-dependent pathway. Furthermore, the results suggest that galanal could inhibit the expression of IDO1 mRNA induced by the IFN-γ-dependent pathway. Therefore, galanal and its derivatives may be useful for the treatment of inflammatory diseases.

### Acknowledgments

The authors thank Dr. Y. Ohta for scientific discussions, and for proofreading the manuscript.

### Author Contributions

Conceived and designed the experiments: RY YY KS. Performed the experiments: RY. Analyzed the data: RY YY. Contributed reagents/materials/analysis tools: SI RF YO MA. Wrote the paper: RY YY YM KS.
4. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, et al. (2002) Tryptophan-degraded carboxylates are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. Journal of Experimental Medicine 196: 439–467.

5. Sharma MD, Hou D-Y, Liu Y, Prendergast GC, Metz R, et al. (2009) Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to Th17-like cells in tumor-draining lymph nodes. Blood 113: 6102–6111.

6. Grommann U, Obrabona C, Fallarino F, Vacca C, Calcinaro F, et al. (2002) CTLA-4 upregulates tryptophan catabolism in vivo. Nature Immunology 3: 1097–1101.

7. Munn DH, Zhou M, Artwood JT, Bondarev I, Convay SJ, et al. (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281: 1107–1109.

8. Palafax D, Llorente I, Alberu J, Torres-Machorro A, Camerlinga N, et al. (2010) The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance in organ transplantation. Transplantation Reviews 24: 160–163.

9. Baoes S, Vaccari M, Fuchs D, Hardy AW, Tsai W-P, et al. (2009) HIV-induced tryptophan catabolism: pathogenic mechanism and target for immunotherapy. Amino Acids 37: 89–89.

10. Romani I, Fallarino F, De Luca A, Montagnoli C, D’Angelo G, et al. (2008) Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 451: 211–U1212.

11. Platten M, Ho PP, Yousser S, Fontoura P, Garren H, et al. (2005) Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310: 850–855.

12. Myint AM, Schwarz MJ, Muller N (2012) The role of the kynurenine metabolism in major depression. Journal of Neural Transmission 119: 245–251.

13. Muller AJ, Scherle PA (2006) Targeting the mechanisms of tumoral immune resistance. Biochemical & Biophysical Research Communications 354.

14. Jeong Y-I, Jung ID, Lee JS, Lee C-M, Lee J-D, et al. (2007) §-Epigallocatechin gallate suppresses indoleamine 2,3-dioxygenase expression in murine dendritic cells. Evidences for the COX-2 and STAT1 as potential targets. Biochemical and Biophysical Research Communications 354.

15. Loeb S, Koenigsrainer A, Zieker D, Bruecher BLDM, Rammensee H-G, et al. (2009) A key in vivo antitumor mechanism of action of natural product-based indoleamine 2,3-dioxygenase. Archives of Biochemistry and Biophysics 291: 789–801.

16. Cerejo M, Andrade G, Roca J, Souza J, Rodrigues C, et al. (2012) A Powerful Yeast-Based Screening Assay for the Identification of Inhibitors of Indoleamine 2,3-Dioxygenase. Journal of Biomolecular Screening 17: 1362–1371.

17. Lancelotti S, Novaes L, De Cristofaro R (2011) Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors. Current Medicinal Chemistry 18: 2205–2214.

18. Smith JR, Evans JK, Wright A, Willows RD, Jamie EF, et al. (2012) Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen. Bioorganic & Medicinal Chemistry 20: 1534–1563.

19. Abe M, Ozawa Y, Morimitsu Y, Kubota K (2009) Mioganal, a Novel Pungent Principle in Muoga (Zingiber mioga Roscoe) and a Quantitative Evaluation of Its Pungency. Bioscience Biotechnology and Biochemistry 72: 2681–2686.

20. Sun T, Chen X-H, Tang Z-D, Cai J, Wang XY, et al. (2010) Novel 1-alkyltryptophan derivatives desorregulate IDO1 and IDO2 mRNA expression induced by interferon-gamma in dendritic cells. Molecular and Cellular Biochemistry 342: 29–34.

21. Saito K, Chen CY, Masana M, Crowley JS, Markey SP, et al. (1993) 4-Chloro-3-hydroxanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-gamma-stimulated monocytes (THP-1 Cells). Biochemical Journal 291: 11–14.

22. Liu X, Shin N, Kobish HK, Yang G, Wang Q, et al. (2010) Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115: 3520–3530.

23. Kumar S, Malachowski WP, DaHaddaw JB, LaLonde JM, Carroll PJ, et al. (2008) Indoleamine 2,3-dioxygenase is the antitumor target for a novel series of potent naphthoquinone-based inhibitors (vol 51, pg 1712, 2008). Journal of Medicinal Chemistry 51: 7325–7325.

24. Banerjee T, DaHaddaw JB, Gaspari P, Sutanto-Ward E, Munn DH, et al. (2008) A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 27: 2851–2857.

25. Matsuoka K, Takeda K, Isaka Y, Unno Y, Sato M, et al. (2010) S-Benzylisothioareas derivatives as small molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorganic & Medicinal Chemistry Letters 20: 5126–5129.

26. Yue EW, Dousty B, Wayland B, Bowser M, Liu X, et al. (2009) Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model. Journal of Medicinal Chemistry 52: 7364–7367.

27. Huang Q, Zheng M, Yang S, Kuang C, Yu C, et al. (2011) Structure-activity relationship and enzyme kinetics study on 3-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors. European Journal of Medicinal Chemistry 46: 5609–5617.

28. Cady SG, Sono M (1991) 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-tryptophan alanine (the oxygen analog of tryptophan), and beta-3-benzo(b)thienyl-DL-tryptophan. Bioscience Biotechnology and Biochemistry 46: 5680–5687.

29. Platten M, Novarese L, Di Cristofaro R (2011) Biochemical Properties of Indoleamine 2,3-Dioxygenase-1 (IDO-1). Australian Journal of Chemistry 66: 40–49.

30. Cerejo M, Andrade G, Roca J, Souza J, Rodrigues C, et al. (2012) A Powerful Yeast-Based Screening Assay for the Identification of Inhibitors of Indoleamine 2,3-Dioxygenase. Journal of Biomolecular Screening 17: 1362–1371.

31. Lancelotti S, Novaes L, De Cristofaro R (2011) Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors. Current Medicinal Chemistry 18: 2205–2214.

32. Banerjee T, DaHaddaw JB, Gaspari P, Sutanto-Ward E, Munn DH, et al. (2008) A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 27: 2851–2857.

33. Matsuno K, Takai K, Isaka Y, Unno Y, Sato M, et al. (2010) S-Benzylisothioareas derivatives as small molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorganic & Medicinal Chemistry Letters 20: 5126–5129.

34. Yue EW, Dousty B, Wayland B, Bowser M, Liu X, et al. (2009) Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model. Journal of Medicinal Chemistry 52: 7364–7367.

35. Huang Q, Zheng M, Yang S, Kuang C, Yu C, et al. (2011) Structure-activity relationship and enzyme kinetics study on 3-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors. European Journal of Medicinal Chemistry 46: 5609–5617.

36. Cady SG, Sono M (1991) 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-tryptophan alanine (the oxygen analog of tryptophan), and beta-3-benzo(b)thienyl-DL-tryptophan. Bioscience Biotechnology and Biochemistry 46: 5680–5687.

37. Platten M, Novarese L, Di Cristofaro R (2011) Biochemical Properties of Indoleamine 2,3-Dioxygenase-1 (IDO-1). Australian Journal of Chemistry 66: 40–49.

38. Platten M, Novarese L, Di Cristofaro R (2011) Biochemical Properties of Indoleamine 2,3-Dioxygenase-1 (IDO-1). Australian Journal of Chemistry 66: 40–49.

39. Platten M, Novarese L, Di Cristofaro R (2011) Biochemical Properties of Indoleamine 2,3-Dioxygenase-1 (IDO-1). Australian Journal of Chemistry 66: 40–49.